NO981135L - Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser - Google Patents

Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser

Info

Publication number
NO981135L
NO981135L NO981135A NO981135A NO981135L NO 981135 L NO981135 L NO 981135L NO 981135 A NO981135 A NO 981135A NO 981135 A NO981135 A NO 981135A NO 981135 L NO981135 L NO 981135L
Authority
NO
Norway
Prior art keywords
tetrahydro
acid addition
addition salts
benzazepine compounds
benzazepine
Prior art date
Application number
NO981135A
Other languages
English (en)
Other versions
NO981135D0 (no
Inventor
Louis Brammer Hansen
Rolf Emil Amsler
Scott Eugene Mcgraw
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO981135D0 publication Critical patent/NO981135D0/no
Publication of NO981135L publication Critical patent/NO981135L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen tilveiebringer en serie av krystallinske salter av (S)- (+)-8-klor-5-(5,6-diklor-2,3-di- hydrobenzofuran-7-yl)-3-metyl-2,3,4,5- tetrahydro-lH-3-benzazepin-7-ol, deres fremstilling og anvendelse som terapeu- tiske midler.
NO981135A 1995-09-15 1998-03-13 Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser NO981135L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK103095 1995-09-15
PCT/DK1996/000383 WO1997010239A1 (en) 1995-09-15 1996-09-12 Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds

Publications (2)

Publication Number Publication Date
NO981135D0 NO981135D0 (no) 1998-03-13
NO981135L true NO981135L (no) 1998-03-13

Family

ID=8100205

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981135A NO981135L (no) 1995-09-15 1998-03-13 Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser

Country Status (13)

Country Link
EP (1) EP0850237A1 (no)
JP (1) JPH11512403A (no)
KR (1) KR19990044648A (no)
CN (1) CN1200121A (no)
AU (1) AU700596B2 (no)
BR (1) BR9610162A (no)
CA (1) CA2231848A1 (no)
CZ (1) CZ77898A3 (no)
HU (1) HUP9900746A3 (no)
IL (1) IL123602A0 (no)
NO (1) NO981135L (no)
PL (1) PL325514A1 (no)
WO (1) WO1997010239A1 (no)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK23392D0 (da) * 1992-02-24 1992-02-24 Novo Nordisk As Heterocykliske forbindelser, deres anvendelse og fremstilling

Also Published As

Publication number Publication date
WO1997010239A1 (en) 1997-03-20
AU700596B2 (en) 1999-01-07
PL325514A1 (en) 1998-08-03
AU6923596A (en) 1997-04-01
NO981135D0 (no) 1998-03-13
CA2231848A1 (en) 1997-03-20
JPH11512403A (ja) 1999-10-26
BR9610162A (pt) 1999-01-05
CN1200121A (zh) 1998-11-25
HUP9900746A2 (hu) 1999-09-28
MX9802000A (es) 1998-08-30
CZ77898A3 (cs) 1998-07-15
KR19990044648A (ko) 1999-06-25
IL123602A0 (en) 1998-10-30
EP0850237A1 (en) 1998-07-01
HUP9900746A3 (en) 1999-11-29

Similar Documents

Publication Publication Date Title
MX9605741A (es) Clorhidrato cristalino del (r)-(-)-2-{n-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzisotiazol-2-il)-butil ]-aminometil} cromano.
SE9504661D0 (sv) New compounds
GT199900140A (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
BG102259A (en) Compostions with controlled paroxetine release
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
AU5313496A (en) Nodulisporic acid derivatives
NO996108L (no) 9-oksinerytromycinderivater
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
PT998287E (pt) Utilizacao de levobupivacaina
ES2162110T3 (es) Derivados de la quinolina antimalaria.
DK0744397T3 (da) Fluorphenylsubstituerede alkenylcarboxylsyre-guanidiner som Na+/K+-antiport-inhibitorer, deres anvendelse som lægemiddel el
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
TR199900730T2 (xx) S�v� alendronat form�lasyonlar�
EP1008345A4 (en) ANTI-ALLERGIC AGENTS
IT1306147B1 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
NO981135L (no) Syreaddisjonssalter av 2,3,4,5-tetrahydro-1H-3-benzazepinforbindelser
ES2170377T3 (es) Composicion que contiene quitosana.
BG103779A (en) Crystallohydrate sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidine-3-ilidenmethyl)-1h-i ndole-2-carboxylic acid
BR9809286A (pt) Processos para redução de fibrinogênio
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
DK0967986T3 (da) Anvendelse af humant alfa1-surt glycoprotein til fremstilling af et farmaceutisk præparat